Cargando…

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330

Preclinical and emerging clinical studies demonstrate that bispecific T-cell engaging (BiTE) antibody constructs can potently lyse targeted tumor cells, but the determinants for their activity remain incompletely understood. Using human acute myeloid leukemia (AML) cell lines engineered to overexpre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laszlo, G S, Gudgeon, C J, Harrington, K H, Walter, R B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558592/ https://www.ncbi.nlm.nih.gov/pubmed/26295610 http://dx.doi.org/10.1038/bcj.2015.68

Ejemplares similares

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk
por: Harrington, Kimberly H., et al.
Publicado: (2015)

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
por: Jitschin, Regina, et al.
Publicado: (2018)

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
por: Kebenko, Maxim, et al.
Publicado: (2018)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
por: Brey, Charlotte U., et al.
Publicado: (2018)

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
por: Hoffman, Lindsey M., et al.
Publicado: (2014)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
por: Laszlo, George S., et al.
Publicado: (2016)

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
por: Ferrari, Francesca, et al.
Publicado: (2015)

CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
por: Ross, Sandra L., et al.
Publicado: (2017)

Correction to: CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110
por: Deisting, Wibke, et al.
Publicado: (2015)

Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway
por: Shen, Ye, et al.
Publicado: (2022)

Bi-Assisted CdTe/CdS Hierarchical Nanostructure Growth for Photoconductive Applications
por: Heo, Kwang, et al.
Publicado: (2015)

Identification of Cytolytic CD161(−)CD56(+) Regulatory CD8 T Cells in Human Peripheral Blood
por: Hu, Dan, et al.
Publicado: (2013)

Maintenance of Functional CD57+ Cytolytic CD4+ T Cells in HIV+ Elite Controllers
por: Phetsouphanh, Chansavath, et al.
Publicado: (2019)

CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma
por: Lei, Wen, et al.
Publicado: (2022)

T-cell responses against CD19(+) pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
por: Feucht, Judith, et al.
Publicado: (2016)

Woodchuck Hepatitis Virus Post-Transcriptional Regulation Element (WPRE) Promotes Anti-CD19 BiTE Expression in Expi293 Cells
por: Moazzami, Reza, et al.
Publicado: (2021)

CD8(+) T cells control SIV infection using both cytolytic effects and non-cytolytic suppression of virus production
por: Policicchio, Benjamin B., et al.
Publicado: (2023)

Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed Immunotherapy
por: Godwin, Colin D., et al.
Publicado: (2021)

The Differentiation and Protective Function of Cytolytic CD4 T Cells in Influenza Infection
por: Brown, Deborah M., et al.
Publicado: (2016)

Characterization of Magnetron Sputtered BiTe-Based Thermoelectric Thin Films
por: Zhang, Zhenxue, et al.
Publicado: (2023)

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
por: Wathikthinnakon, Methi, et al.
Publicado: (2022)

Repression of phagocytosis by human CD33 is not conserved with mouse CD33
por: Bhattacherjee, Abhishek, et al.
Publicado: (2019)

CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta
Publicado: (1991)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
por: Meckler, Joshua F., et al.
Publicado: (2023)

Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer
por: Cachot, Amélie, et al.
Publicado: (2021)

CD4+ cytolytic T cell clone confers protection against murine malaria
Publicado: (1990)

Inflammation Enhances IL-2 Driven Differentiation of Cytolytic CD4 T Cells
por: Workman, Aspen M., et al.
Publicado: (2014)

The Cytolytic Activity of Vaginolysin Strictly Depends on Cholesterol and Is Potentiated by Human CD59
por: Zilnyte, Milda, et al.
Publicado: (2015)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
por: Fedyk, Eric R., et al.
Publicado: (2020)

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
por: Subklewe, Marion, et al.
Publicado: (2014)

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
por: Stanchina, Michele, et al.
Publicado: (2019)

Cytolytic CD4(+) and CD8(+) Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease
por: Bolivar-Wagers, Sara, et al.
Publicado: (2022)

Author Correction: Repression of phagocytosis by human CD33 is not conserved with mouse CD33
por: Bhattacherjee, Abhishek, et al.
Publicado: (2020)

Comparison of AMG 416 and cinacalcet in rodent models of uremia
por: Walter, Sarah, et al.
Publicado: (2014)

Ligand induced switching of the band alignment in aqueous synthesized CdTe/CdS core/shell nanocrystals
por: Vale, Brener R. C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8l1a1li10ecgjtv5acc1smq2br